MGF (Mechano Growth Factor) vs MK-2866 (Ostarine)
A side-by-side research comparison of MGF (Mechano Growth Factor) and MK-2866 (Ostarine) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MGF (Mechano Growth Factor) | MK-2866 (Ostarine) |
|---|---|---|
| Full name | Mechano Growth Factor (IGF-1Ec splice variant) | Ostarine / Enobosarm (MK-2866) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Investigational (not approved; banned in sport) |
| Mechanism | Unique E-domain activates quiescent satellite cells for proliferation. Distinct from IGF-1Ea which drives differentiation. PEGylated form extends short half-life. | Selectively binds androgen receptors in muscle and bone tissue, stimulating anabolic (muscle-building) signaling while having relatively less effect on the prostate and other androgen-sensitive tissues than testosterone. |
| Molecular weight | 2,867 Da (synthetic fragment) | 389.33 Da |
| Half-life | 5-7 min (native) / 24-48h (PEGylated) | ~24 hours |
| Bioavailability | High (local IM) | Oral |
| Typical dose | 100-200 mcg PEG-MGF | Commonly cited 10-25 mg/day (research) |
| Frequency | 2-3x per week | Once daily |
| Route | Intramuscular (local) | Oral |
MGF (Mechano Growth Factor) reported benefits
- Satellite cell activation
- Muscle-specific growth
- Repair response enhancement
- Synergistic with training
- Local hypertrophy
MK-2866 (Ostarine) reported benefits
- Lean muscle preservation/gain
- Bone density support (research)
- Less androgenic than steroids
- Studied for muscle wasting
Related comparisons
Research and educational reference only. Not medical advice.